High Performance Cell & Gene Therapies
We are a biotech company combining microfluidics, digitalization and bioengineering to make high quality biological therapies at affordable cost and minimized environmental impact.
SMALL IS POWERFUL
Therapeutic cells can multiply in the patient's body. This allows high purity miniature doses cellular therapies to expand in vivo up to the amounts needed to obtain therapeutic effects.
Leveraging this specificity, our approach consists in optimizing and miniaturizing cellular therapies and their manufacturing. This way minute amounts of resources are spent without compromising efficacy.
As a result costs and environmental impact of these innovative therapies are drastically reduced.
In healthy patients T cells detect and kill sick cells. Cancer cells escape T cells recognition thanks to mutations.
CAR-T cells (T cells equipped with a Chimeric Antigen Receptor) are artificially hardcoded to recognize and kill cancer cells.
Multiple CAR-T therapies are commercially available but their access is limited by low manufacturing throughput and high prices.
We use our exclusive optimization and miniaturization technologies to improve CAR-T therapies in clinically validated applications ("generic CAR-T") to boost their accessibility.
Hematopoietic stem cells (HSCs) are mothers to all blood cells including erythrocytes and lymphocytes.
We develop high quality genetically edited HSCs to cure an undisclosed hereditary blood disease.
This development will be translatable:
genetically edited HSCs can be used to treat multiple genetic diseases, including hemoglobinopathies and immune deficiencies.
Macrophages are versatile cells. They exhibit abilities to survive solid tumor microenvironment, to trigger inflammation and to absorb and digest debris or infected cells.
CAR-Macrophages (CAR-M) are artificially directed against a cancerous target by a chimeric antigen receptor. CAR-M are still in their clinical infancy, however specific abilities of macrophages make them a promising approach to treat solid tumors resisting to available therapies.
We are currently in the early-stage development of CAR-M with our miniaturization and optimization technologies.
World's First Microfluidic Cell Factory
To realize our ambitions we have developed Lakhesys, a universal solution to optimize and produce cell and gene therapies. Lakhesys is world's first fully automated microfluidic cell factory. It is protected by 8 patent families.
Lakhesys uniquely allows us to screen and optimize manufacturing process in a clinical grade fashion, cheaply and rapidly.
Once the process is optimized Lakhesys allows us to produce massively in parallel,
up to 100 minibatches simultaneously in a conventional size manufacturing room.
Therefore, optimization, miniaturization and parallelization considerably improve both the manufacturing and the development of advanced therapies.
Lakhesys development was supported by the European Union and France
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 850358 and from French Minister of Education and Innovation and BPI France as part of i-Lab 2018 prize.
Join us ! Send your resume at firstname.lastname@example.org
DR JÉRÉMIE LAURENT
Head of Software
DR GIULIA GHINATTI
Head of Biology
Head of Hardware and Manufacturing
DR XUE HOU
Head of Microtechnologies
DR ANTOINE LAGARDE
Senior Process Engineer
DR CAROLINE RICHARD
Head of Regulatory Strategy and Business Development
Senior Software Engineer